precisionmedicineonline18m
Roche Looks Forward to Itovebi Approval in Europe Amid Steady Q4 Revenue Growth
The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.
Sarepta could be down on patient death in FDA database, says RBC Capital
RBC Capital analyst Brian Abrahams says shares of Sarepta (SRPT) could be trading lower today on an FDA database update that ...
Sarepta’s Elevidys Phase 3 Study Raises Concerns: Kapoor Issues Sell Rating Amid Market Applicability and Control Group Disparities
Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Sell rating on Sarepta Therapeutics (SRPT – Research Report). The associated ...